Health & Fitness
Health and FitnessHealth and Fitness 
Fri, December 9, 2011
Thu, December 8, 2011
Transcept Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
Transcept Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December... -- POINT RICHMOND, Calif., Dec. 8, 2011 /PRNewswire/ --
Transcept Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
POINT RICHMOND, Calif., Dec. 8, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at the Oppenheimer & Co. Healthcare Conference in New York on December 13, 2011 at 10:15 a.m. ET.
(Logo: [ http://photos.prnewswire.com/prnh/20101102/SF93452LOGO ])
A live audio webcast and replay of this presentation may be accessed at [ http://www.veracast.com/webcasts/opco/healthcare2011/23104664.cfm ] and on the Transcept Investor webpage at [ www.transcept.com ].
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience.
Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product and is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. Intermezzo is not indicated for the treatment of middle-of-the-night insomnia when the patient has fewer than 4 hours of bedtime remaining before the planned time of waking. Patients should be cautioned about possible combined effects with CNS-depressant drugs. Intermezzo should not be taken with alcohol. The most commonly reported adverse reactions in clinical trials with Intermezzo were headache, nausea and fatigue. Transcept and Purdue have entered into a collaboration agreement for the development and commercialization of Intermezzo in the United States.
Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder.
For further information about Transcept, please visit [ www.transcept.com ].
Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]
SOURCE Transcept Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.transcept.com ]